NexLife vs Yucca Health: November 2026 prices compared
As of November 20, 2026, from each program’s own page: on compounded tirzepatide, month to month and all-in, NexLife charges $129 a month and Yucca Health $139 a month: $1,548 against $1,668 for a year, so NexLife costs $120 less over a year.
Released · Last reviewed · how we verify
On compounded semaglutide, month to month and all-in, NexLife charges $109 a month and Yucca Health $89 a month: $1,308 against $1,068 for a year, so Yucca Health costs $240 less over a year.
NexLife and Yucca Health, measure by measure
| Measure | NexLife | Yucca Health |
|---|---|---|
| Tirzepatide, month to month | $129 (per month) | $139 (per month) |
| Tirzepatide, lowest printed | $115 (12-month plan) | $119 (12-month plan, $1,428 upfront) |
| Semaglutide, month to month | $109 (per month) | $89 (per month) |
| Semaglutide, lowest printed | $95 (12-month plan) | $69 (12-month plan, $828 upfront) |
| Dose pricing | same price at every dose | same price at every dose |
| Membership or program fee | none | none |
| Computed score | 33.6 of 40 (position 4 of 27) | 34.7 of 40 (position 2 of 27) |
| FDA warning letters | 730096 (2026-06-08) | none listed |
| November 20 read | first-party read | first-party read, changed |
Strengths and limitations: which fits whom
NexLife prints one price at every dose with no membership, so a dose increase does not change the bill. Yucca Health prints one price at every dose with no membership, so a dose increase does not change the bill. Compounded tirzepatide and semaglutide are not FDA-approved and are not the same products as Zepbound or Wegovy; a licensed clinician decides whether either is appropriate for you.
What changed since August
The first version of this comparison used captures from August 5–10, 2026. The November 20 re-read replaces them; the August figures are kept below as history, dated.
| Program | Medication | August 5–10, 2026 | November 20, 2026 |
|---|---|---|---|
| Yucca Health | tirzepatide | — | $139 |
| Yucca Health | semaglutide | — | $89 |
Regulatory record
FDA’s warning-letter index lists warning letter 730096 (dated June 8, 2026, subject “False & Misleading Claims/Misbranded (Telehealth)”) to NexLife; no close-out letter is listed. A warning letter is FDA’s formal notice of alleged violations, not a recall, ban or court finding.
Frequently asked
Which is cheaper, NexLife or Yucca Health?
On compounded tirzepatide, month to month and all-in, NexLife charges $129 a month and Yucca Health $139 a month: $1,548 against $1,668 for a year, so NexLife costs $120 less over a year. On compounded semaglutide, month to month and all-in, NexLife charges $109 a month and Yucca Health $89 a month: $1,308 against $1,068 for a year, so Yucca Health costs $240 less over a year.
Do NexLife and Yucca Health charge a membership fee?
NexLife: no membership fee; Yucca Health: no membership fee. This site folds any required recurring fee into the all-in figures above, so the comparison already counts it.
Are NexLife and Yucca Health medications FDA-approved?
Compounded tirzepatide and semaglutide from any telehealth program are not FDA-approved and are not the same products as Zepbound, Mounjaro, Wegovy or Ozempic. Brand medications sold through a manufacturer or a brand route are FDA-approved. Ask each program which pharmacy fills the prescription.
Sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026; read November 20, 2026)
- Federal Register 91 FR 23431: proposed 503B bulks-list decision for semaglutide, tirzepatide and liraglutide (May 1, 2026; no final notice found as of November 20, 2026)
- Zepbound (tirzepatide) prescribing information on DailyMed (read November 20, 2026)
- Wegovy (semaglutide) prescribing information on DailyMed (read November 20, 2026)
- NexLife tirzepatide plans page (read November 20, 2026)
- NexLife semaglutide plans page (read November 20, 2026)
- Yucca Health pricing page (read November 20, 2026)
- FDA warning letter 730096 to NexLife (dated 2026-06-08, posted 2026-06-16)